Potential Inequities in New Medical Technologies
By Eric B. Kmiec and Jonathan Marron,
Scientific American
| 03. 28. 2020
As headline-catching new technologies emerge—like tools to “edit” our DNA—researchers, doctors, patients and the general public are excited about the future of medicine and the research that informs its practice. For some, there are obvious and critical conversations taking place about the ethics of this research, including how we do it (think “CRISPR babies” in China) and the potential for edits (intentional or otherwise) that could be passed on to future generations.
These conversations are important, but they can overshadow another equally important question. Will all patients have equal access to these new technologies?
That question requires us to look back at the blemished history of medical research and health care that has resulted in some patients—based on their race, gender, income and other factors—having poorer access to health care and poorer health in general. In some cases, this is because the system neglected them. In others, because the system blatantly abused them. The question we must ask is: Will new treatments continue or even worsen deeply rooted disparities? Or will we lay the groundwork for future treatments that...
Related Articles
By Elizabeth Dias, The New York Times | 08.14.2024
Republicans may be backing away from abortion, but these activists have a strategy, with or without Trump.
The pivot seems clear. The Republican Party of the post-Roe era is sidelining anti-abortion activists. Project 2025, the conservative blueprint with innovative abortion...
By Alison Motluk, Broadview | 08.15.2024
Canada has been slow to end anonymous paternity, but cheap and easy genetic testing makes staying unknown all but impossible.
It was by accident that Jason Tarshis learned the truth about his origins. At 49, he bought a home genetic...
By Sydney Lupkin and Asma Khalid, NPR | 08.15.2024
The White House unveiled the fruits of months of negotiations between the government and pharmaceutical companies: new, lower Medicare prices for 10 blockbuster drugs.
The discounts range from 79% for diabetes drug Januvia to 38% for blood cancer drug Imbruvica...
By Irin Carmon, New York | 09.14.2024
At Tuesday night’s debate, seemingly stung by Kamala Harris’s assertion that IVF treatments have been curtailed “under Donald Trump’s abortion bans,” the former Republican president declared, “I have been a leader on IVF, which is fertilization. The IVF — I...